301. 黄斑ジストロフィー Macular dystrophy Clinical trials / Disease details
臨床試験数 : 45 / 薬物数 : 46 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02941991 (ClinicalTrials.gov) | January 16, 2013 | 20/10/2016 | A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Follow-up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Stargardt's Macular Dystrophy | Biological: hESC-RPE | Astellas Institute for Regenerative Medicine | NULL | Completed | 18 Years | N/A | All | 12 | Phase 1/2 | United Kingdom |
| 2 | NCT01469832 (ClinicalTrials.gov) | December 13, 2011 | 8/11/2011 | Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Stargardt's Macular Dystrophy | Biological: MA09-hRPE | Astellas Institute for Regenerative Medicine | NULL | Completed | 18 Years | N/A | All | 12 | Phase 1/Phase 2 | United Kingdom |